Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BIO-TECHNE Corp    TECH

BIO-TECHNE CORP

(TECH)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

BIO-TECHNE CORP : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2019 | 04:35pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Bio-Techne Corporation has expanded the size of the Board of Directors from eight to nine members and elected Dr. Rupert Vessey to the company's Board of Directors as an independent director.

Rupert Vessey, MA, BM BCh, FRCP, DPhil is currently the President of Global Research and Early Development at Celgene, and is anticipated to hold that position at Bristol-Myers Squibb once its acquisition of Celgene is final. Before joining Celgene, Dr. Vessey held various research and development senior management positions at Merck. Dr. Vessey holds an MA in physiological sciences and a BM BCh in clinical medicine from Oxford University where he completed his DPhil at the Institute for Molecular Medicine, Oxford along with additional clinical training at various hospitals in the UK. He is a member of the Royal College of Physicians of London UK.

There are no arrangements or understandings between Dr. Vessey and any other persons pursuant to which he was selected as a director. Additionally, there are no transactions involving the Company and Dr. Vessey that Bio-Techne would be required to report pursuant to Item 404(a) of Regulation S-K. Dr. Vessey will be entitled to receive compensation for his Board service in accordance with the company's standard compensation arrangements for non-employee directors, which are described under the caption "Director Compensation" in the company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on September 11, 2018, pro-rated for a partial year of service in accordance with company policy.


Item 8.01 Other Events


A copy of the press release issued by Bio-Techne Corporation on June 25, 2019, announcing Dr. Vessey's election is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits



    (d) Exhibits

    99.1     Press Release, dated June 25, 2019, announcing election of Dr.
           Vessey as a director.




--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIO-TECHNE CORP
07/11BIO-TECHNE ANNOUNCES COMMERCIAL RELE : A Multiplex In Situ Hybridization Assay F..
PR
07/09BIO TECHNE : CEO Chuck Kummeth Wins Entrepreneur Of The Year® 2019 Award In The ..
PR
06/26BIO TECHNE : China Recognized With "Decade of Contribution Award"
PR
06/25BIO-TECHNE CORP : Change in Directors or Principal Officers, Other Events, Finan..
AQ
06/25BIO TECHNE : Appoints Rupert Vessey to Board of Directors
PR
06/17BIO TECHNE : FDA Grants Breakthrough Device Designation To Bio-Techne's ExoDx&tr..
PR
06/13BIO TECHNE : Receives Approval To Offer The ExoDx™ Prostate Intelliscore&t..
PR
06/04BIO TECHNE : To Acquire B-MoGen Biotechnologies Inc.
PR
06/03BIO TECHNE : To Present At The Goldman Sachs 40th Annual Global Healthcare Confe..
PR
05/29BIO TECHNE : TECH) CFO Sells 35,000 Shares of Stock
AQ
More news